Harrow, Inc. (HROW)
| Market Cap | 1.11B -26.7% |
| Revenue (ttm) | 303.25M +21.3% |
| Net Income | -28.49M |
| EPS | -0.76 |
| Shares Out | 37.53M |
| PE Ratio | n/a |
| Forward PE | 25.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 453,460 |
| Open | 29.00 |
| Previous Close | 29.09 |
| Day's Range | 28.75 - 29.74 |
| 52-Week Range | 25.76 - 54.85 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 62.25 (+110.87%) |
| Earnings Date | Nov 9, 2026 |
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for p... [Read more]
Financial Performance
In 2025, Harrow's revenue was $272.30 million, an increase of 36.41% compared to the previous year's $199.61 million. Losses were -$5.14 million, -70.60% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price target is $62.25, which is an increase of 110.87% from the latest price.
News
Harrow to Participate in Two Investor Conferences in November
NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will particip...
Harrow price target lowered to $56 from $59 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Harrow (HROW) to $56 from $59 and keeps a Buy rating on the shares. The firm notes the company reported a mixed quarter,…
Harrow reports Q3 EPS 25c, consensus 30c
Reports Q3 revenue $99.3M, consensus $98.59M. “The third quarter delivered the second-half acceleration we anticipated,” said Mark L. Baum, Chairman and Chief Executive Officer of Harrow (HROW). “Bran...
Harrow backs FY26 revenue view $350M-$365M, consensus $349.66M
Cuts FY26 adjusted EBITDA view to over $40M from $80M-$100M. Baum continued, “We expect the fourth quarter to be Harrow’s (HROW) strongest on record and that second-half revenue will exceed…
Harrow Earnings Call Transcript: Q3 2026
Q3 revenue reached a record $99.3 million, while FY revenue guidance was reaffirmed and Q4 is expected to set a new high. Adjusted EBITDA guidance was reduced as investment spending and weaker margins weigh on near-term profitability.
Harrow Earnings release: Q3 2026
Harrow released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Harrow Quarterly report: Q3 2026
Harrow has published its Q3 2026 quarterly earnings report on November 10, 2026.
Harrow Shareholder letter: Q3 2026
Harrow has published a letter to shareholders covering Q3 2026, which was released on November 10, 2026.
Harrow Slides: Q3 2026
Harrow has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 10, 2026.
Harrow Announces Third Quarter 2026 Financial Results
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approx...
PHIL partners with Harrow to launch HarrowRx
PHIL announced its partnership with Harrow (HROW) to launch HarrowRx, Harrow’s new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow’s branded ophtha...
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care Portfolio
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease mana...
Harrow Launches HarrowRx Platform
NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a pre...
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its finan...
Harrow Closes Acquisition of TYRVAYA®
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for D...
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts...
Harrow Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Management outlined a long-term, five-year strategic vision with a focus on under-promising and over-delivering, highlighted by a $250 million quarterly revenue goal for 2027. Key growth drivers include G-MELT, IHEEZO, and VEVYE, with significant market expansion expected from new product launches, acquisitions, and upcoming clinical data.
Leerink bullish on Harrow, initiates with an Outperform
As previously reported, Leerink initiated coverage of Harrow (HROW) with an Outperform rating and $45 price target The firm highlights synergistic ophthalmology portfolio, with near-term growth opport...
Harrow initiated with an Outperform at Leerink
Leerink initiated coverage of Harrow (HROW) with an Outperform rating and $45 price target
Harrow to Participate in Three Investor Conferences in September
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will partici...
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients...
Harrow Earnings Call Transcript: Q2 2026
Revenue grew 11% YoY in Q2 to $70.7M, with strong sequential growth and improved product economics. Multiple growth drivers, including VEVYE, IHEEZO, and TRIESENCE, are set for accelerated H2 performance. Full-year guidance of $350–$365M revenue and $80–$100M adjusted EBITDA reiterated.
Harrow Earnings release: Q2 2026
Harrow released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Harrow Quarterly report: Q2 2026
Harrow has published its Q2 2026 quarterly earnings report on August 11, 2026.
Harrow Slides: Q2 2026
Harrow has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.